Skip to main content
. 2022 Mar 30;13(5):e00487. doi: 10.14309/ctg.0000000000000487

Figure 5.

Figure 5.

Overall survival of patients. (a and b) Survival rates of patients with KRAS G12D mutations (red line) and other mutations or wild-type (green line). The mutations were detected with either EUS-FNA or ctDNA samples (P = 0.001 and P = 0.0008, respectively). (c and d) Survival rates of patients with wild-type KRAS (black line) and in those with KRAS mutations (red line). There was no significant difference of the MSTs between EUS-FNA and plasma ctDNA groups (P = 0.7088 and P = 0.3076, respectively). *P < 0.05, ***P < 0.001. ctDNA, circulating tumor DNA; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration; MST, median survival time; WT, wild type.